According to press reports, the U.S. District Court for the Southern District of New York has agreed to investigate Gotham ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

The Mason Capital fund, which owns 3.174% of Grifols' (GRF) class A shares, has expressed its support for the blood products ...

Health Minister Khaled Abdel Ghaffar met on Sunday, June 1st, 2025, with Magdy Amin, Chairman of Grifols Egypt, to discuss expanding cooperation in haematology and the national plasma derivatives ...

Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ: GRFS) class A ...

A New York court has found enough evidence to proceed with a defamation lawsuit filed by Grifols against short seller Gotham ...

Grifols (GRFS) secures a win in its defamation lawsuit against Gotham City Research in the U.S. Read more here.

A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company ...

Change of the Chief Executive Officer (CEO) of Biotest AG28-May-2025 / 17:00 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS ...

At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.

The FDA cleared an investigational new drug application for a phase 2 trial of GRF312 ophthalmic solution, an immunoglobulin ...

The positive outlook is based on expectations that Grifols’s operating performance and credit metrics will continue to improve over the next 12-18 months. Specifically, its gross leverage is ...